Psychiatry Investig > Volume 11(1); 2014 > Article |
AD: antidepressant, AAP: atypical antipsychotic agent, ECT: Electroconvulsive therapy, TAP: typical antipsychotic agent, MS: mood stabilizer, PF: psychotic features, SSRI: selective serotonin reuptake inhibitor, SNRI: serotonin-norepinephrine reuptake inhibitor, AP: antipsychotic agent, TCA: tricyclic antidepressant, Quetiapine XR: extended release formulation of quetiapine, MAOI: monoamine oxidase inhibitor, KMAP-DD: Korean Medication Algorithm Project for Depressive Disorder, APA: American Psychiatric Association, CANMAT: Canadian Network for Mood and Anxiety Treatments, NICE: National Institute for Health and Clinical Excellence, TMAP: Texas Medication Algorithm Project, WFSBP: World Federation of Societies of Biological Psychiatry
AD: antidepressant, AAP: atypical antipsychotic agent, TAP: typical antipsychotic agent, MAOI: monoamine oxidase inhibitor, TCA: tricyclic antidepressant, SNRI: serotonin-norepinephrine reuptake inhibitor, AP: antipsychotic agent, KMAP-DD: Korean Medication Algorithm Project for Depressive Disorder, APA: American Psychiatric Association, CANMAT: Canadian Network for Mood and Anxiety Treatments, NICE: National Institute for Health and Clinical Excellence, TMAP: Texas Medication Algorithm Project, WFSBP: World Federation of Societies of Biological Psychiatry
AD: antidepressant, AAP: atypical antipsychotic agent, MS: mood stabilizer, SNRI: serotonin-norepinephrine reuptake inhibitor, TCA: tricyclic antidepressant, SSRI: selective serotonin reuptake inhibitor, MAOI: monoamine oxidase inhibitor, ECT: Electroconvulsive therapy, KMAP-DD: Korean Medication Algorithm Project for Depressive Disorder, APA: American Psychiatric Association, CANMAT: Canadian Network for Mood and Anxiety Treatments, NICE: National Institute for Health and Clinical Excellence, TMAP: Texas Medication Algorithm Project, WFSBP: World Federation of Societies of Biological Psychiatry
AD: antidepressant, AAP: atypical antipsychotic agent, MDD: major depressive disorder, SSRI: selective serotonin reuptake inhibitor, KMAP-DD: Korean Medication Algorithm Project for Depressive Disorder, APA: American Psychiatric Association, CANMAT: Canadian Network for Mood and Anxiety Treatments, NICE: National Institute for Health and Clinical Excellence, TMAP: Texas Medication Algorithm Project, WFSBP: World Federation of Societies of Biological Psychiatry
AD: antidepressant, AAP: atypical antipsychotic agent, SSRI: selective serotonin reuptake inhibitors, SNRI: serotonin-norepinephrine reuptake inhibitors, MAOI: monoamine oxidase inhibitors, TCA: tricyclic antidepressants, KMAP-DD: Korean Medication Algorithm Project for Depressive Disorder, APA: American Psychiatric Association, CANMAT: Canadian Network for Mood and Anxiety Treatments, NICE: National Institute for Health and Clinical Excellence, TMAP: Texas Medication Algorithm Project, WFSBP: World Federation of Societies of Biological Psychiatry
AD: antidepressant, AAP: atypical antipsychotic agent, MS: mood stabilizer, KMAP-DD: Korean Medication Algorithm Project for Depressive Disorder, APA: American Psychiatric Association, CANMAT: Canadian Network for Mood and Anxiety Treatments, NICE: National Institute for Health and Clinical Excellence, TMAP: Texas Medication Algorithm Project, WFSBP: World Federation of Societies of Biological Psychiatry
Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives2020 March;17(3)
The Development of the Korean Medication Algorithm for Major Depressive Disorder2005 September;2(2)